• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

石蜡分枝杆菌引起的有症状肺部感染罕见病例。

A Rare Case of Symptomatic Pulmonary Infection Caused by Mycobacterium paraffinicum.

作者信息

Vinh Huy, Sutaria Nirja, Adlakha Arun

机构信息

Family Medicine, Edward Via College of Osteopathic Medicine, Spartanburg, USA.

Internal Medicine, Atrium Health, Charlotte, USA.

出版信息

Cureus. 2025 Jun 29;17(6):e86982. doi: 10.7759/cureus.86982. eCollection 2025 Jun.

DOI:10.7759/cureus.86982
PMID:40734880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12306510/
Abstract

is a non-tuberculous mycobacterium (NTM) shown to be a human pathogen in recent years. Here, we present a rare case of pulmonary infection caused by in a 69-year-old female patient who presented with symptoms, initially thought to be from a chronic obstructive pulmonary disease (COPD) exacerbation. From our literature review, this is a case of presenting as a human pathogen. The patient's medical history included COPD, obstructive sleep apnea (OSA), and obesity. Her medical management included inhaled corticosteroid (ICS)/ long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA), and nocturnal continuous positive airway pressure (CPAP) device. For her acute worsening of symptoms, she was treated with oral ciprofloxacin and prednisone for possible COPD exacerbation from presumed pneumonia. However, she showed no improvement in her pulmonary symptoms. Follow-up computed tomography (CT) imaging of the chest showed new scattered "Tree in Bud" opacities. Sputum studies and acid-fast bacilli (AFB) cultures revealed the growth of She was treated with a combination of oral clarithromycin, moxifloxacin, and rifabutin. This case highlights the importance of keeping atypical mycobacteria, such as NTM, as a cause of pulmonary infection in the differential diagnosis, particularly in patients with chronic pulmonary conditions who present with persistent and/or unexplained respiratory symptoms. Early identification is crucial for appropriate treatment to improve patient outcomes.

摘要

是一种近年来被证明为人病原体的非结核分枝杆菌(NTM)。在此,我们报告一例69岁女性患者由其引起的肺部感染罕见病例,该患者最初出现的症状被认为是慢性阻塞性肺疾病(COPD)加重所致。通过我们的文献回顾,这是一例表现为人病原体的病例。患者的病史包括COPD、阻塞性睡眠呼吸暂停(OSA)和肥胖。她的药物治疗包括吸入性糖皮质激素(ICS)/长效β受体激动剂(LABA)、长效毒蕈碱拮抗剂(LAMA)以及夜间持续气道正压通气(CPAP)设备。对于她症状的急性加重,因推测肺炎可能导致COPD加重,她接受了口服环丙沙星和泼尼松治疗。然而,她的肺部症状并无改善。胸部的后续计算机断层扫描(CT)成像显示出现了新的散在“树芽征”混浊。痰液检查和抗酸杆菌(AFB)培养显示 的生长。她接受了口服克拉霉素、莫西沙星和利福布汀的联合治疗。该病例强调了在鉴别诊断中将非典型分枝杆菌(如NTM)作为肺部感染病因的重要性,特别是对于患有慢性肺部疾病且出现持续和/或无法解释的呼吸道症状的患者。早期识别对于采取适当治疗以改善患者预后至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/e77b1a7b7f45/cureus-0017-00000086982-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/05011c0113e6/cureus-0017-00000086982-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/73944f94bcd7/cureus-0017-00000086982-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/9352569c9e11/cureus-0017-00000086982-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/e77b1a7b7f45/cureus-0017-00000086982-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/05011c0113e6/cureus-0017-00000086982-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/73944f94bcd7/cureus-0017-00000086982-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/9352569c9e11/cureus-0017-00000086982-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/12306510/e77b1a7b7f45/cureus-0017-00000086982-i04.jpg

相似文献

1
A Rare Case of Symptomatic Pulmonary Infection Caused by Mycobacterium paraffinicum.石蜡分枝杆菌引起的有症状肺部感染罕见病例。
Cureus. 2025 Jun 29;17(6):e86982. doi: 10.7759/cureus.86982. eCollection 2025 Jun.
2
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
3
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.长效毒蕈碱拮抗剂(LAMA)联合长效β-激动剂(LABA)与 LABA 联合吸入皮质类固醇(ICS)治疗稳定期慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD012066. doi: 10.1002/14651858.CD012066.pub3.
4
Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性皮质类固醇联合吸入长效β2-激动剂和长效抗胆碱能药物治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD011600. doi: 10.1002/14651858.CD011600.pub3.
5
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).长效毒蕈碱拮抗剂(LAMA)联合长效β受体激动剂(LABA)与LABA联合吸入性糖皮质激素(ICS)用于稳定期慢性阻塞性肺疾病(COPD)的比较
Cochrane Database Syst Rev. 2017 Feb 10;2(2):CD012066. doi: 10.1002/14651858.CD012066.pub2.
6
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.慢性阻塞性肺疾病的长效吸入疗法(β受体激动剂、抗胆碱能药物和类固醇):一项网状荟萃分析。
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.
7
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.对于慢性阻塞性肺疾病患者,每日一次长效β₂受体激动剂/吸入性糖皮质激素联合吸入器与吸入性长效毒蕈碱拮抗剂的比较
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012355. doi: 10.1002/14651858.CD012355.pub2.
8
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.联合使用皮质类固醇和长效β2受体激动剂的单一吸入器与长效β2受体激动剂治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD006829. doi: 10.1002/14651858.CD006829.pub2.
9
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.吸入性糖皮质激素与慢性阻塞性肺疾病患者的肺炎风险
Cochrane Database Syst Rev. 2014 Mar 10;2014(3):CD010115. doi: 10.1002/14651858.CD010115.pub2.
10
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.囊性纤维化患者非结核分枝杆菌肺部感染的抗生素治疗
Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039.

本文引用的文献

1
Clinical Presentation and Management of Pulmonary Infection Caused by Mycobacterium paraffinicum.石蜡分枝杆菌引起的肺部感染的临床表现与管理
Cureus. 2024 Oct 4;16(10):e70813. doi: 10.7759/cureus.70813. eCollection 2024 Oct.
2
A rare case of lymphadenitis and pulmonary disease caused by .由……引起的一例罕见的淋巴结炎和肺部疾病。 (原文此处不完整,翻译只能到此程度)
Respirol Case Rep. 2019 Mar 12;7(4):e00414. doi: 10.1002/rcr2.414. eCollection 2019 May.
3
Respiratory infections due to nontuberculous mycobacterias.非结核分枝杆菌引起的呼吸道感染。
Med Clin (Barc). 2018 Mar 9;150(5):191-197. doi: 10.1016/j.medcli.2017.07.010. Epub 2017 Sep 18.
4
A case of pulmonary infection due to from the Amazon Region.一例源自亚马逊地区的肺部感染病例。 (注:原英文句子“due to from”表述有误,正确可能是“due to...”或“from...”,这里按纠正后的理解翻译)
IDCases. 2017 Jul 12;10:1-3. doi: 10.1016/j.idcr.2017.07.001. eCollection 2017.
5
Pulmonary Disease Caused by Non-Tuberculous Mycobacteria.非结核分枝杆菌引起的肺部疾病
Respiration. 2016;91(5):386-402. doi: 10.1159/000445906. Epub 2016 May 21.
6
Mycobacterium paraffinicum causing symptomatic pulmonary infection.引起症状性肺部感染的石蜡分枝杆菌。
J Clin Microbiol. 2014 Apr;52(4):1281-3. doi: 10.1128/JCM.03107-13. Epub 2014 Jan 22.
7
Characterization of "Mycobacterium paraffinicum" associated with a pseudo-outbreak.与一次假性暴发相关的“石蜡分枝杆菌”的特性分析
J Clin Microbiol. 2008 May;46(5):1850-3. doi: 10.1128/JCM.02079-07. Epub 2008 Mar 26.
8
Mycobacterium paraffinicum n. sp., a bacterium isolated from soil.石蜡分枝杆菌新种,一种从土壤中分离出的细菌。
Appl Microbiol. 1956 Nov;4(6):310-5. doi: 10.1128/am.4.6.310-315.1956.